- Home
- CTOR vs PMVP Comparison
CTOR vs PMVP Comparison
Compare CTOR & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- PMVP
- Stock Information
- Founded
- CTOR 2021
- PMVP 2013
- Country
- CTOR United States
- PMVP United States
- Employees
- CTOR N/A
- PMVP N/A
- Industry
- CTOR
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- CTOR
- PMVP Health Care
- Exchange
- CTOR NYSE
- PMVP Nasdaq
- Market Cap
- CTOR 89.9M
- PMVP 71.9M
- IPO Year
- CTOR N/A
- PMVP 2020
- Fundamental
- Price
- CTOR $0.67
- PMVP $1.11
- Analyst Decision
- CTOR Strong Buy
- PMVP Strong Buy
- Analyst Count
- CTOR 2
- PMVP 3
- Target Price
- CTOR $4.50
- PMVP $5.33
- AVG Volume (30 Days)
- CTOR 166.3K
- PMVP 105.5K
- Earning Date
- CTOR 05-21-2025
- PMVP 03-03-2025
- Dividend Yield
- CTOR N/A
- PMVP N/A
- EPS Growth
- CTOR N/A
- PMVP N/A
- EPS
- CTOR N/A
- PMVP N/A
- Revenue
- CTOR N/A
- PMVP N/A
- Revenue This Year
- CTOR N/A
- PMVP N/A
- Revenue Next Year
- CTOR N/A
- PMVP N/A
- P/E Ratio
- CTOR N/A
- PMVP N/A
- Revenue Growth
- CTOR N/A
- PMVP N/A
- 52 Week Low
- CTOR $0.55
- PMVP $1.11
- 52 Week High
- CTOR $49.00
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- PMVP 26.51
- Support Level
- CTOR N/A
- PMVP $1.21
- Resistance Level
- CTOR N/A
- PMVP $1.30
- Average True Range (ATR)
- CTOR 0.00
- PMVP 0.06
- MACD
- CTOR 0.00
- PMVP -0.01
- Stochastic Oscillator
- CTOR 0.00
- PMVP 0.00
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.